N4P N4 Pharma Plc

TIDMN4P

RNS Number : 6200C

N4 Pharma PLC

24 February 2022

24 February 2022

N4 Pharma Plc

("N4 Pharma" or the "Company")

Notice of Annual General Meeting

and

Posting of Annual Report and Accounts

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for cancer treatments and vaccines, announces that the Company's audited accounts for the year ended 31 December 2021, together with the notice of Annual General Meeting ("AGM"), are now available on the Company's website

www.n4pharma.com   and will be posted to shareholders today. 

The AGM will be held at 11.00am on 24 March 2022 at Shakespeare Martineau LLP, 6th Floor 60 Gracechurch Street, London, EC3V 0HR.

Enquiries:

 
 N4 Pharma Plc                               Via IFC Advisory 
  Nigel Theobald, CEO 
  Luke Cairns, Executive Director 
 
 SP Angel Corporate Finance LLP              Tel: + 44 (0)20 3470 
  Nominated Adviser and Joint Broker          0470 
  Matthew Johnson/Caroline Rowe (Corporate 
  Finance) 
  Vadim Alexandre/Rob Rees (Corporate 
  Broking) 
 
 Turner Pope Investments (TPI) Limited       Tel: +44 (0)20 3657 
  Joint Broker                                0050 
  Andy Thacker 
 IFC Advisory Limited                        Tel: +44 (0)20 3934 
  Financial PR                                6630 
  Graham Herring 
  Zach Cohen 
 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec(R).

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec(R) as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCSEUFMDEESEIE

(END) Dow Jones Newswires

February 24, 2022 02:00 ET (07:00 GMT)

N4 Pharma (LSE:N4P)
Historical Stock Chart
Von Jun 2024 bis Jul 2024

N4 Pharma (LSE:N4P)
Historical Stock Chart
Von Jul 2023 bis Jul 2024